Biotechnology stocks have been back in the spotlight since the beginning of the year. Successes in research and market approvals for new drugs could provide fresh impetus. Is the sector worth a look now?
Artikel zu “Vertex”
Despite correction: long-term upward trend of biotech companies intact
Biotechnology shares have seen better times. Despite the most recent corrections, hopes for growth in the biotechnology sector remain very high. We spoke to Harald Kober, fund manager of ERSTE STOCK BIOTEC, about the latest developments.
Tailwind for biotechnology companies
Biotechnology shares have been among the top performers in the past ten years. After the above-average performance from 2010 to the beginning of 2015, hedge funds set off a consolidation that is now coming to an end. The NASDAQ biotechnology index, the most important barometer for biotech shares, has gained 25% in the year to date (source: Reuters Datastream, as of 31 August 2017).